Skip to main content

Table 6 PSA bounce in literature

From: Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

Authors Pub N Median Follow-up (months) Hormone Therapy (%) EBRT
(%)
Bounce Def Rate
(%)
Time to onset
(months)
Magnitude
(ng/ml)
Duration
(months)
Predictive factors
Aaltomaa [10] 2009 444 81.6 yes (18) Yes (4) ≥ 0.2 ng/ml 13 19.2 1.4 -- Age < 65, risk group, PSA nadir < 0.5
Bostancic et al. [11] 2007 164 65 yes (37.2) no ≥ 0.2 ng/ml 26.9 18.9 0.5 8.7 Age,125 I >103 Pd *
Cavanagh et al. [12] 2000 591 55 no yes ≥ 0.2 ng/ml 35.8 24.8 -- -- NC
Ciezki et al. [13] 2006 162 73 yes (38.2) no ≥ 0.2 ng/ml 46.3 15 -- -- Age < 70 *
Caloglu [26] 2010 820 58 Yes (22.2) no ≥ 0.2 ng/ml
≥ 0.4
≥ 0.6
≥ 0.8
30.1
19.6
12.8
9.5
17.4
16.3
16.2
15.7
-- -- Age, N of PSAs
Critz et al. [27] 2003 1,011 72 no all ≥ 0.1 ng/ml 41 18 0.4 9 Age
Crook et al. [14] 2007 275 44 no no ≥ 0.2 ng/ml 40 15.6 0.76 6.8 Age *
Das et al. [15] 2002 186 33 no yes (25.8) ≥ 15% 62 26.4 0.6 12 --
Kanai et al. [17] 2009 86 32 no no ≥ 0.4 ng/ml 33 15 0.6 -- Age < 67, D90 > 180 Gy
Kuban et al. [18] 2006 2,693 63 no no ≥ 0.2 ng/ml 17 -- 0.9 14 --
Hinnen et al. [16] 2011 975 78 ¤ Yes (19) no ≥ 0.2 ng/ml 32.3 19.2 -- -- --
Makarewicz et al * [19] 2006 71 32 no Yes (100) ≥ 0.2 ng/ml 31 13.5 0.28 -- Age, i PSA, V200
McGrath et al [28]* 2009 191 48 Yes (46%) no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 2 ng/ml
44
34
21
3
-- 0.2
0.3
0.6
2.6
15
--
--
25
--
Merrick et al. [20] 2003 218 46 no yes (57.1) ≥ 0.2 ng/ml 23.9 16.3 0.9 16 Age, TNM, V150
PSA post brachy
Mitchell et al. [21] 2008 205 45 no no ≥ 0.2 ng/ml 37 14.8 0.91 -- Age
Morita et al. [29] 2004 200 35 no no ≥ 0.1 ng/ml 40 13 0.3 -- --
Patel et al. [22] 2004 295 38 yes (62.4) no ≥ 0.2 ng/ml 28 19.4 0.5 -- Age < 65 *
Pickles et al. [30] 2006 449 48 yes (70) no all 84 13 -- -- --
Satoh et al. [24] 2008 388 -- no no ≥ 0.1 ng/ml
≥ 0.4 ng/ml
≥ 35%
50.8
23.5
19.4
-- 0.4 -- --
Stock et al. [25] 2003 373 48 no no ≥ 0.1 ng/ml
≥ 0.4 ng/ml
≥ 35%
31
17
20
19.5
19.5
20.5
-- -- Age < 65, prostate volume > 35 cm3 (bounce > 0.4)*
Thompson [31] 2010 1,006 54 Yes (65.7%) no +2 then nadir ≤ 0.5 ng/ml 2.5 20.6 -- -- Age
Toledano et al. [32, 33] 2006 295 42 yes (42.4) no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
55
49
32
19 0.8 11.2 Age < 70, D90 > 200 Gy *
Zwahlen [34] 2010 194 60 no no ≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 15%
≥ 35%
50
34
11
9
14
14
16
15.5
05
0.8
1.9
2
12
13
18
21.5
Age
Mazeron (this study) 2012 198 64 no no ≥ 0.1 ng/ml
≥ 0.2 ng/ml
≥ 0.4 ng/ml
≥ 15%
≥ 35%
48.5
35.9
25.8
52
36.4
17 0.6 14 Age, PSA 6 weeks
  1. *: series including patients treated with HDR brachytherapy. --: non reported in publication. ¤: mean Abbreviations: Pub year = date of publication; N = number of patients; F-up, follow-up; Hormon, hormonal therapy. i PSA: pre treatment value of PSA. N of PSA: amount of PSA values recorded per patient